Emisphere Technologies and AAIPharma to Expand Use of Eligen Technology
Jun 12, 2009 BioPharm Bulletin
Emisphere Technologies, Inc. (Cedar Knolls, NJ), a biopharmaceutical company that focuses on delivery of therapeutic molecules using its Eligen Technology, and AAIPharma, Inc. (Wilmington, NC), have formed a strategic alliance intended to expand the application of Emisphere’ s Eligen Technology and AAIPharma’s drug development services.
Emisphere’s proprietary Eligen Technology is a delivery method for therapeutic molecules and nutritional supplements. These therapeutic molecules, both large and small, may be currently delivered by injection. The Eligen Technology can be applied by oral administration or other routes, such as buccal, rectal, inhalational, intra-vaginal, or transdermal.
AAIPharma, Inc. is a global provider of pharmaceutical product development services currently provides drug product formulation services to Emisphere.
Rate this page
Would you recommend this page to a friend?
Your original vote has been tallied and is included in the ratings results.
